Breakthrough's Comment On NICE's Draft Decision Not To Recommend Lapatinib (Tyverb) F

[News]

The National Institute for Health & Clinical Excellence (NICE) have issued a draft decision not to recommend lapatinib (Tyverb) for use on the NHS. A final decision is expected later this year. Dr Alexis Willett, Policy Manager at Breakthrough Breast Cancer, says: "This will be disappointing for some women with advanced breast cancer. Breakthrough hopes that if further results from clinical trials are positive this decision will be reviewed in future.

More... (http://www.medicalnewstoday.com/articles/141282.php)

[Ellie F]

Disappointing is an understatement! What happens to all the women waiting till more research proves it's effective. It may be too late by then.Will be interested how the other UK breast cancer charities respond and more importantly what they intend to do to lobby NICE.